Company shares 온라인 바카라사이트’s business strategy in a corporate briefing session on April 30
[by Ji, Yong Jun] Kangstem Biotech announced on April 23 that it will present Phase 1 clinical trial results for ‘OSCA,’ a fundamental treatment candidate for osteoarthritis, at the ‘2025 Osteoarthritis Research Society International (OARSI)’ conference, scheduled to take place from April 24 to 27 at Songdo Convensia in Incheon.
OARSI is recognized as the world’s leading academic society in the field of osteoarthritis, drawing participation from over 1,000 experts across academia and industry representing more than 50 countries. The company further announced that Professor Seo Dae-geun of Kyung Hee University Medical Center’s Department of Orthopedics, who led the Phase 1 온라인 바카라사이트 trial of OSCA, will present the study’s findings during the conference.
The data to be presented at the conference will include imaging evaluations conducted six months post-administration, with corresponding MRI images being disclosed publicly for the first time. Additionally, the presentation will cover evaluation 온라인 바카라사이트, including pain index assessment, knee function and physical activity, pain management efficacy, overall joint function, global osteoarthritis improvement, and changes in local cartilage regions at each follow-up visit.
“This presentation at OARSI is a meaningful achievement, as it represents the first introduction of OSCA’s therapeutic potential for osteoarthritis to the global academic community,” a Kangstem Biotech official said. “Building on this opportunity, we aim to secure our global market competitiveness by actively participating in international conferences throughout the year while pursuing tangible business 온라인 바카라사이트 such as technology licensing.”
OSCA is an advanced bio-fusion therapeutic complex designed for the fundamental treatment of knee osteoarthritis. It combines cord blood-derived mesenchymal stem cells and acellular cartilage matrix. In non-온라인 바카라사이트 studies conducted using a goat model, a single intra-articular injection, administered without surgical intervention, demonstrated structural improvements such as cartilage and subchondral bone regeneration.
In the Phase 1 온라인 바카라사이트 trial, OSCA demonstrated pain relief, functional improvement, and cartilage regeneration. Based on these results, Kangstem Biotech is conducting a Phase 2a 온라인 바카라사이트 trial to further evaluate the efficacy of OSCA as a fundamental treatment, previously confirmed in animal experiments and Phase 1 온라인 바카라사이트 trials, which is currently being administered to patients at seven Korean institutions.
Conversely, Kangstem Biotech will hold a public investor relations (IR) on April 30 at the Ruby Hall on the 2nd floor of the conference center of FKI Tower (main building of the Federation of Korean Industries). During this event, the company will provide an overview of key announcements made at the OARSI conference, including an analysis of the Phase 1 온라인 바카라사이트 trial results for OSCA, as well as updates on the current status of its business operations.